Novavax shares jumped more than 15% on Monday after the company secured a long-awaited U.S. regulatory approval for its COVID ...

President Donald Trump's tax cut and spending bill faces a critical stress test on Wednesday as Republicans in the U.S. House ...

Novavax had expected full approval for broader use by April 1, after the FDA reviewed data from a 30,000-person clinical ...

Novavax can finally breathe a sigh of relief – at least a small one. The Food and Drug Administration approved the company's ...

The U.S. Food and Drug Administration approved Novavax's COVIDd-19 vaccine with age restrictions after a six-week delay.

After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter ...

WASHINGTON — The Food and Drug Administration has issued a long-awaited approval of Novavax’s COVID-19 vaccine but with ...

The agency narrowed who can get the shot and added new study requirements that could cost the company tens of millions.

Novavax's full FDA approval for NUVAXOVID is a transformative milestone, unlocking a $175M Sanofi payment and validating ...

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years ...

The approval marks a significant milestone for Novavax Inc. (NASDAQ:NVAX), aligning with the changing regulatory landscape ...

The approval of Nuvaxovid for use in older and high-risk adults will generate around $175 million in milestone payments from ...